"The speakers argued that massive AI capital expenditures will lead to margin compression for big tech companies as depreciation expenses begin to hit balance sheets."

"The long-term valuation of Eli Lilly is threatened by the inevitable transition of GLP-1 weight-loss drugs to cheap generics."

"A major expansion of Medicare coverage will offer select weight loss drugs for a $50 monthly co-pay, potentially benefiting up to 20 million eligible seniors."

"The GLP-1 drug class represents a structural shift in global healthcare due to its wide-ranging metabolic, cardiovascular, and potential cognitive benefits."

"The guest argued that lowering the price of GLP-1 drugs to $150-$200 will dramatically reduce chronic illness rates and return money to the American taxpayer within two years."

"Novo Nordisk's Wegovy pill is capturing the majority of the early GLP-1 oral market share over Eli Lilly's competing offering."